

ADVANCED TECHNOLOGIES & TREATMENTS FOR DIABETES 17-20 FEBRUARY 2021, PARIS, FRANCE



HE 14TH INTERNATIONAL CONFERENCE ON

Abstract #49 UTILITY OF FLASH GLUCOSE MONITORING TO DETERMINE GLUCOSE LOAD IN PATIENTS WITH TYPE 2 DIABETES

PARIS

Dr. Tonolo Logout

<u>M.A. Taras</u>¹, S. Cherchi¹, I. Campesi², G. Tonolo¹ ¹ASSL Olbia-ATS Sardegna, DIABETOLOGY, Olbia, Italy, ²Pharmacy University of Sassari, Gender Medicine, Sassari, Italy

AS051-Glucose Sensors Abstract Submission

Background and Aims

Postprandial glycemic load (GL) is difficult to quantify accurately in a determined food. We previously showed that sourdough bread, compared to a bread with yeast for bread making elicits a lower postprandial glycemic and insulinemic response. **AIMS:** to evaluate in T2DM patients: 1) GL to three different doughs : X = prepared with a functional alkaline water, Y = Sourdough Bread (Y) and W = commercial leavening; 2) the utility of flash glucose monitoring (FGM) to measure GL. **Methods**

Ten T2DM on diet (6 Males, diabetes duration 10,8±3,8 years with no complications, Hba1c less than 7.0%), after 12 hours fasting, consumed 180 grams study breads leavened for 48 (X),8 (Y) and 2 hours (W) with 250 ml water (random order, single blind, in different days). All patients had a Fast Glucose Monitoring running from three days before the first test. Insulin was determined by capillary blood (10-12 drops) obtained at basal and at the peak glucose concentration.

Results

GL, peak glucose and peak insulin concentration were significantly (p < 0.05) lower for X and Y vs W, without significant differences between X and Y.

Conclusions

1) bread with alkalized water has the same low GL of Sourdough Bread compared to traditional bread with an easier management of the leavening / maturation period, 2) FGM is a reliable method for determining the glycemic load in response to a carbohydrate meal in type 2 diabetic patients.

Affirmations

1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after final submission deadline and I am aware that it will be published exactly as submitted. 2. Submission of the abstract constitutes my consent to publication (e.g. Conference website, program, other promotions, etc.) 3. As the Abstract Submitter, I warrant and represent that I am the sole owner or have the rights of all the information and content ("Content") provided to ATTD 2021 and Kenes Group (Hereafter: "The Organizers"). The publication of the abstract does not infringe any third-party rights including, but not limited to, intellectual property rights. 4. As the Abstract Submitter, I grant the Organizers a royalty-free, perpetual, irrevocable non-exclusive license to use, reproduce, publish, translate, distribute, and display the Content. 5. I understand that the presenting author must be a registered participant. 6. The Organizers reserve the right to remove from any publication an abstract that does not comply with the above. 7. I understand that I must select a specific Topic for my abstract allocation. Although the Committee will work hard to honor this selection, this cannot be guaranteed. The Committee reserves the right to change the Topic under which the abstract was originally submitted. 8. I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.





THE 14TM INTERNATIONAL CONFERENCE ON ADVANCED TECHNOLOGIES & TREATMENTS FOR DIABETES



17-20 FEBRUARY 2021, PARIS, FRANCE